CorMedix CRMD 深 沪
等待开盘 10-01 09:30:00 美东时间
11.63
-0.220
-1.86%
华盛通- 最 高12.29
- 今 开12.08
- 成交量 191.50万股
- 最 低 11.61
- 昨 收 11.85
- 总市值 8.68亿
- 52周最高 17.43
- 市盈率 静 --
- 换手率 2.57%
- 52周最低 5.60
- 委 比 52.24%
- 总股本 7464.90万
- 历史最高 52.00
- 量 比 0.78
- 振 幅 5.74%
- 历史最低 0.73
- 每 手 1
- 风险率 2.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO
CorMedix Inc. announced the completion of enrollment for its Phase III ReSPECT trial evaluating the efficacy of REZZAYO® (rezafungin) in preventing fungal infections in adult patients undergoing allogeneic blood and marrow transplantation. Sponsored by Mundipharma, the trial aims to assess once-weekly rezafungin against a standard antimicrobial regimen. Topline results are expected in Q2 2026. REZZAYO is approved in the U.S. for treating candidem...
09-29 12:30
美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
09-10 18:01
Analyst Expectations For Cormedix's Future
During the last three months, 6 analysts shared their evaluations of Cormedix (...
09-10 02:01
JMP Securities Reiterates Market Outperform on Cormedix, Maintains $22 Price Target
JMP Securities analyst Jason N. Butler reiterates Cormedix (NASDAQ:CRMD) with a Market Outperform and maintains $22 price target.
09-09 20:37
CorMedix Announces Strategic Minority Investment in Talphera
CorMedix Inc. has made a $5 million strategic minority equity investment in Talphera, Inc. for its Niyad product, which is under development as an anticoagulant for continuous renal replacement therapy. The investment supports Talphera's Phase 3 study and pre-launch preparations, with CorMedix gaining exclusive negotiation rights and a Board seat. CorMedix aims to enhance its acute care portfolio through this synergistic partnership.
09-08 12:30
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
09-03 01:35
CorMedix Revised Guidance Of Pro Forma 2025 Combined Revenues To $325M-$350M Vs. Consensus Of $215.14M, Melinta Therapeutics Deal Expected to be near-term accretive to EPS with double-digit accretion expected in 2026
Transaction expected to be near-term accretive to EPS with double-digit accretion expected in 2026; annual run-rate synergies expected to be ~$35 to $45 millionRevised Full Year Financial GuidancePro forma 2025 Revenue:
09-02 19:39
CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team
CorMedix Inc. announced the completion of its acquisition of Melinta Therapeutics, expanding its portfolio with seven drug products and pipeline opportunities. The deal is expected to generate $325–$350 million in 2025 pro forma revenues and enhance profitability, with potential peak sales for REZZAYO™ prophylaxis exceeding $200 million. Key leadership roles have been finalized, and annual synergies are projected at $35–$45 million. The acquisiti...
09-02 11:30
CorMedix to Participate in Upcoming Investor Conferences
CorMedix Inc. announced that its senior management will participate in fireside chats at the Cantor Global Healthcare Conference on September 5 and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10. CorMedix, a biopharmaceutical company focused on developing life-saving therapeutic products, has successfully commercialized its lead product, DefenCath® (taurolidine and heparin), following FDA approval in November 2023. Th...
08-28 12:30
Elliott Management Bets Against S&P 500, Nasdaq 100, Nvidia Stock In Second Quarter
Elliott Management places new bets against the market in the second quarter, while taking a new long position in Hewlett Packard Enterprise.
08-15 07:24
